Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS: Talactoferrin Alfa in Severe Sepsis
2010-023986-23Phase 2Terminated
- Sponsor
- Agennix AG
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis comparing Talactoferrin alfa with Placebo (2 arms). Primary endpoint: 28-day all-cause mortality. Started Feb 2011; status: terminated.
02
Drugs
lactoferrin
03
Conditions
sepsis
Beyond the preview
Go deeper on 2010-023986-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023986-23.